69366EGP
- Active ingredient
- ribociclib
- Strength
- 200 mg
- Form
- tablet
- Manufacturer
- novartis
- Route
- oral.solid
Uses
Indicated in combination with endocrine therapy for HR-positive, HER2-negative early, advanced, or metastatic breast cancer in appropriate patients.
Do not use if
No specific absolute contraindications are listed in prescribing information, except hypersensitivity considerations.
Side effects
Common adverse effects include neutropenia, nausea, fatigue, diarrhea, hepatotoxicity, and QT prolongation.
Warnings
Monitor for interstitial lung disease, severe skin reactions, QT prolongation, hepatotoxicity, and neutropenia.
How it works
Selective inhibitor of cyclin-dependent kinases 4 and 6 that blocks cell cycle progression and tumor proliferation.
Storage
Store at room temperature in the original package.